Fomivirsen Sodium
drug drugOn this page
Also known as Fomivirsen eicosasodium saltFomivirsen naISIS 2922ISIS-2922Vitravene preservative freeFomivirsen (ISIS 2922)
Summary
Fomivirsen Sodium (CHEMBL1201512) is an approved oligonucleotide; indicated across 1 condition including cytomegalovirus retinitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligonucleotide
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201512 |
| Name | Fomivirsen Sodium |
| Type | Oligonucleotide |
| Max phase | 4 |
Also known as: Fomivirsen eicosasodium salt, Fomivirsen na, Fomivirsen sodium, ISIS 2922, ISIS-2922, Vitravene preservative free, Fomivirsen (ISIS 2922), FOMIVIRSEN SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| cytomegalovirus retinitis | 2 | MONDO:0000878 | EFO:1001302 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002156 | PHASE2 | COMPLETED | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) |
| NCT00002356 | PHASE2 | COMPLETED | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes |
| NCT00002187 | Not specified | COMPLETED | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis |
| NCT00002355 | Not specified | COMPLETED | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: cytomegalovirus retinitis